(Q63302039)

2

0 references

Nadia Harbeck

3

0 references

John Martens

4

0 references

Nils Brunner

5

0 references

Christoph Thomssen

6

0 references

Jacqueline A. Hall

7

0 references

Roberto Salgado

8

0 references

Juergen Dittmer

9

0 references

Anneke Geurts-Moespot

10

0 references

M. Joe Duffy

11

0 references

Fred C.G.J. Sweep

12

0 references

Manfred Schmitt

The molecular pathology of cancer

13

0 references

publication date

March 2012

0 references

published in

EJC supplements

0 references

volume

10

0 references

issue

1

0 references

page(s)

120-127

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Integration of Translational Research in the European Organization for Research and Treatment of Cancer Research (EORTC) Clinical Trial Cooperative Group Mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Urokinase-type plasminogen activator antigen and early relapse in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Dissemination risk index based on plasminogen activator system components in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Tumor markers in breast cancer- European Group on Tumor Markers recommendations.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

TIMP-1 as a tumor marker in breast cancer--an update

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Cancer-associated carbonic anhydrases and their inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Telomere Maintenance Mechanisms in Liposarcomas: Association with Histologic Subtypes and Disease Progression

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Genes associated with breast cancer metastatic to bone

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Lung metastasis genes couple breast tumor size and metastatic spread.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Genes that mediate breast cancer metastasis to the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Comparison of prognostic gene expression signatures for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Quality control of cathepsin-D measurement by the EORTC Receptor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

The performance of a commercial radioligand binding assay for the epidermal growth factor receptor is comparable to the EORTC standard assay

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

Integrating Collection of Biospecimens in Clinical Trials: The Approach of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021

REporting recommendations for tumor MARKer prognostic studies (REMARK).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6349%2812%2970021-6

7 January 2021